In an interim order, Sebi restrained the Vadodara-based Par Medicine and Chemical compounds Ltd (PDCL) from executing the Enterprise Switch Settlement (BTA) signed on February 14, 2025, with Phal-Jig Superb Chemical compounds Pvt Ltd (PJFCPL) for Rs 95 crore.
The client agency is a part of PDCL’s promoter group, as per the order.
Sebi directed the Nationwide Inventory Alternate to nominate an unbiased registered valuer to re-examine the enterprise endeavor utilizing recognised valuation requirements and acquire a equity opinion from a service provider banker.
PDCL, its administration and signatories to the BTA have been directed to stop and desist from getting into into any transaction which can result in disposal of belongings till additional instructions, the regulator mentioned.
Each the valuation report and equity opinion together with NSE’s suggestion should be submitted inside 15 days from the date of receipt of equity opinion, it added. “…prima facie view that the correctness of valuation methodology adopted by PDCL must be independently re-examined to establish whether or not the valuation is honest and reflective of true worth of the endeavor being transferred by way of the proposed hunch sale. “Additionally it is a matter of proven fact that the market capitalisation of PDCL has eroded by nearly 70 per cent for the reason that announcement of the hunch sale on the said valuation,” Sebi’s whole-time member Kamlesh Chandra Varshney mentioned within the order.
PDCL has knowledgeable Sebi that the proposed hunch sale is sought to be accomplished by September 20.
Subsequently, Sebi mentioned it’s essential to problem interim instructions restraining PDCL from continuing with any step which will outcome within the alienation, sale, or disposal of its belongings, together with the implementation of the BTA dated February 14, 2025, till completion of additional investigation on this matter.
“If the proposed hunch sale transaction is allowed to proceed, it might trigger grave injustice to the general public shareholders for the reason that transaction would grow to be irreversible upon execution.
“Thus, I discover that there exist ample grounds to type a prima facie opinion that the proposed hunch sale transaction by PDCL could also be detrimental to the pursuits of public shareholders and warrants pressing intervention by Sebi within the type of interim instructions,” Varshney mentioned.
as a Dependable and Trusted Information SupplyThe Securities and Alternate Board of India (Sebi) had acquired a grievance alleging {that a} proposed hunch sale of enterprise by PDCL shouldn’t be compliant with the relevant legislation and is prejudicial to the pursuits of the general public shareholders.
